Latest filings (excl ownership)
15-12B
Securities registration termination
8 Oct 20
EFFECT
Notice of effectiveness
30 Sep 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
POS AM
Prospectus update (post-effective amendment)
28 Sep 20
25-NSE
Exchange delisting
28 Sep 20
8-K
Completion of Acquisition or Disposition of Assets
28 Sep 20
SC 14D9/A
Tender offer solicitation (amended)
28 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
28 Sep 20
SC 14D9/A
Tender offer solicitation (amended)
22 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
22 Sep 20
SC 14D9/A
Tender offer solicitation (amended)
17 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
14 Sep 20
SC 14D9/A
Tender offer solicitation (amended)
14 Sep 20
SC 14D9
Tender offer solicitation
28 Aug 20
SC TO-T
Third party tender offer statement
28 Aug 20
SC14D9C
Written communication relating to third party tender offer
21 Aug 20
SC TO-C
Information about tender offer
18 Aug 20
SC14D9C
Written communication relating to third party tender offer
17 Aug 20
8-K
Sanofi to acquire Principia Biopharma
17 Aug 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
8-K
Principia Biopharma Reports Second Quarter 2020
6 Aug 20
8-K
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
26 Jun 20
8-K
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
12 Jun 20
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 20
10-Q
2020 Q1
Quarterly report
6 May 20
8-K
Principia Biopharma Reports First Quarter 2020 Financial Results
6 May 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
8-K
Other Events
24 Apr 20
S-8
Registration of securities for employees
10 Mar 20
10-K
2019 FY
Annual report
10 Mar 20
8-K
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results
10 Mar 20
8-K
Other Events
7 Feb 20
8-K
Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases
10 Jan 20
8-K
Principia Presents Consistent Positive Data of PRN1008
9 Dec 19
10-Q
2019 Q3
Quarterly report
5 Nov 19
8-K
Principia Biopharma Reports Third Quarter Financial Results
5 Nov 19
8-K
Entry into a Material Definitive Agreement
18 Oct 19
Latest ownership filings
SC 13G/A
Cormorant Asset Management, LP
16 Feb 21
SC 13D/A
GLAXOSMITHKLINE PLC
1 Oct 20
4
Shawn Tomasello
28 Sep 20
4
Patrick Machado
28 Sep 20
4
Simeon George
28 Sep 20
4
Shao-Lee Lin
28 Sep 20
4
Daniel J. Becker
28 Sep 20
4
Alan Colowick
28 Sep 20
4
Stefani Wolff
28 Sep 20
4
Dolca Thomas
28 Sep 20
4
Roy C. Hardiman
28 Sep 20
4
CHRISTOPHER Y CHAI
28 Sep 20
4
David M Goldstein
28 Sep 20
4
Martin Babler
28 Sep 20
4
Roy C. Hardiman
22 Sep 20
SC 13G/A
FMR LLC
10 Sep 20
SC 13D
BIOTECHNOLOGY VALUE FUND L P
25 Aug 20
4
Dolca Thomas
20 Aug 20
4
CHRISTOPHER Y CHAI
20 Aug 20
4
PARTNERS L P/IL BVF
20 Aug 20
3
PARTNERS L P/IL BVF
20 Aug 20
SC 13G
BIOTECHNOLOGY VALUE FUND L P
19 Aug 20
4
David M Goldstein
12 Aug 20
4
Dolca Thomas
17 Jul 20
4
Alan Colowick
2 Jul 20
4
Martin Babler
25 Jun 20
4
Stefani Wolff
17 Jun 20
4/A
Stefani Wolff
17 Jun 20
4/A
Stefani Wolff
17 Jun 20
4
Roy C. Hardiman
15 Jun 20
4
Shawn Tomasello
8 Jun 20
4
Patrick Machado
8 Jun 20
4
Simeon George
8 Jun 20
4
Shao-Lee Lin
8 Jun 20
4
Daniel J. Becker
8 Jun 20
4
Alan Colowick
8 Jun 20
4
CHRISTOPHER Y CHAI
21 May 20
4
David M Goldstein
8 May 20
4
Alan Colowick
5 May 20
4
Stefani Wolff
18 Mar 20